Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712802 | 1.00 | CA2 (0.65) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL7583937 | 1.00 | CA2 (0.65) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL6097748 | 1.00 | CA2 (0.65) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL3686551 | 1.00 | CA2 (0.65) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL9633629 | 1.00 | CA2 (0.65) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL1547462 | 0.98 | CA2 (0.68) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| 2-Ethylhexanoic Acid SCHEMBL9736177 | 0.92 | CA2 (0.80) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL2233014 | 0.91 | CA2 (0.71) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL14359878 | 0.91 | CA2 (0.77) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL14360381 | 0.91 | CA2 (0.77) | CA2MAPK1CHRM1AKR1A1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | SPITFIRE PHARMA LLC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250134963-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | SPITFIRE PHARMA LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12171806-B2 | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists | SPITFIRE PHARMA LLC (MD) | 2024-12-24 | — | — | US | disclosed |
| CN-117202924-A | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balance agonists | 斯皮特弗尔制药有限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4255564-A1 | THERAPEUTIC REGIMENS AND METHODS FOR LOWERING BLOOD GLUCOSE AND OR BODY WEIGHT USING GLP-1R AND GCGR BALANCED AGONISTS | Spitfire Pharma LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230104501-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | SPITFIRE PHARMA LLC (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4106796-A1 | GLP-1R AND GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | Spitfire Pharma LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022125598-A1 | THERAPEUTIC REGIMENS AND METHODS FOR LOWERING BLOOD GLUCOSE AND OR BODY WEIGHT USING GLP-1R AND GCGR BALANCED AGONISTS | SPITFIRE PHARMA LLC (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171806-B2 | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists | GLP1R, GCGR, GIPR | CA2 4024/4885MAPK1 569/4885CHRM1 1340/4885 |
| US-20250134963-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | GLP1R, GCGR, GIPR | CA2 4024/4885MAPK1 569/4885CHRM1 1340/4885 |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | GLP1R, GCGR, GPR119 | CA2 3857/4885MAPK1 741/4885CHRM1 748/4885 |
| US-20230104501-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | GLP1R, GCGR, GIPR | CA2 4024/4885MAPK1 569/4885CHRM1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.